| Prev Close | 2.10 |
| Open | 2.13 |
| Day Low/High | 2.02 / 2.16 |
| 52 Wk Low/High | 1.90 / 8.50 |
| Volume | 27.16K |
| Avg Volume | 619.60K |
| Exchange | OTC |
| Shares Outstanding | 5.67M |
| Market Cap | 12.20M |
| EPS | -6.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits
Soligenix Receives Japanese Patent For ThermoVax® Vaccine Heat Stabilization Platform Technology
Patent describes application of ThermoVax® with RiVax®
Soligenix Receives FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Trial Targeted to Begin in Second Quarter of 2017
Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results
Highlighted by Revenues of $10.4 Million
Soligenix Receives Positive Scientific Advice From The European Medicines Agency For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Follows UK Health Ministry's Granting SGX942 Promising Innovative Medicine Designation in the Treatment of Oral Mucositis
Soligenix Announces Extension Of Development Agreement With Emergent BioSolutions
Supported with NIAID Contract Funding of up to $24.7 million
Soligenix Advances Collaboration With IDT Biologika
Supported with NIAID Contract Funding of up to $24.7 million
Soligenix Announces Investor Webcast Event: Origins Of Innate Defense Regulators And Review Of The SGX942 Phase 2 Study Results In Oral Mucositis
Friday, December 16, 2016, from 8:30-9:30 am ET
Soligenix Announces Positive Long-Term Follow-up Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Study data supports advancing development to pivotal Phase 2b/3 program
Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis
Agreement Includes Greater China and Other East Asia Markets
Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
Patents provide broad protection for the innate defense regulator technology platform
